Modern analytical approaches employing high-resolution mass spectrometry (MS) facilitate the generation of a vast amount of structural data of highly complex glycoproteins. Nevertheless, systematic interpretation of this data at different structural levels remains an analytical challenge. The glycoprotein utilized as a model system in this study, human chorionic gonadotropin (hCG), exists as a heterodimer composed of two heavily glycosylated subunits. In order to unravel the multitude of glycoforms of recombinant hCG (drug product Ovitrelle), we combine established techniques, such as released glycan and glycopeptide analysis, with novel approaches employing high-performance liquid chromatography-mass spectrometry (HPLC-MS) to characterize protein subunits and native MS to analyze the noncovalent hCG complex. Starting from the deconvoluted mass spectrum of dimeric hCG comprising about 50 signals, it was possible to explore the chemical space of hCG glycoforms and elucidate the complexity that hides behind just 50 signals. Systematic, stepwise integration of data obtained at the levels of released glycans, glycopeptides, and subunits using a computational annotation tool allowed us to reveal 1031 underlying glycoforms. Additionally, critical quality attributes such as sialylation and core fucosylation were compared for two batches of Ovitrelle to assess the potential product variability.

Different manufacturing processes and storage conditions of biotherapeutics can lead to a significant variability in drug products arising from chemical and enzymatic post-translational modifications (PTMs), resulting in the co-existence of a plethora of proteoforms with different physicochemical properties. To unravel the heterogeneity of these proteoforms, novel approaches employing strong cation-exchange (SCX) high-performance liquid chromatography (HPLC) hyphenated to mass spectrometry (MS) using a pH gradient of volatile salts have been developed in recent years. Here, we apply an established SCX-HPLC-MS method to characterize and compare two rituximab-based biotherapeutics, the originator MabThera® and its Indian copy product Reditux™. The study assessed molecular differences between the two drug products in terms of C-terminal lysine variants, glycosylation patterns, and other basic and acidic variants. Overall, MabThera® and Reditux™ displayed differences at the molecular level. MabThera® showed a higher degree of galactosylated and sialylated glycoforms, while Reditux™ showed increased levels of oligomannose and afucosylated glycoforms. Moreover, the two drug products showed differences in terms of basic variants such as C-terminal lysine and N-terminal truncation, present in Reditux™ but not in MabThera®. This study demonstrates the capability of this fast SCX-HPLC-MS approach to compare different drug products and simultaneously assess some of their quality attributes.

Aquazol poly (2-ethyl-oxazoline) is a tertiary aliphatic amide, with physical and chemical properties that are exploited in a variety of ways, from pharmaceutical applications to the conservation of cultural heritage. In this study, we evaluated the use of Aquazol as a new binder for retouching paint in the restoration of artworks. Aquazol 500 admixed with various formulations of organic red pigments was used to prepare paint replicas which were artificially aged and investigated by a multi-analytical approach based on analytical pyrolysis coupled with gas chromatography and mass spectrometry (Py-GC/MS), and thermogravimetry (TG), complemented by FTIR and LIBS spectroscopy. This is the first study on the ageing phenomena of Aquazol 500 using analytical pyrolysis and thermogravimetric analysis. The influence of the pigments' components on the pyrolysis behavior of Aquazol was also investigated. The paint replicas did not show significant modifications during artificial ageing. This thus highlights the optimal properties of Aquazol 500 as a binder for retouching, in addition to its already established suitability as a filler or consolidant in the restoration of artifacts. Interestingly, when Aquazol 500 is used in formulations containing organic pigments, Aquazol-pigment interactions are observed, strongly depending on the pigment used

No abstract

No abstract